1.Neurological diseases/disorders other than multiple system atrophy, such as Parkinson's disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraplegia, corticobasal degeneration, vascular parkinsonism, normal pressure hydrocephalus, drug-induced or post-encephalitic parkinsonism.
2. The subject was diagnosed with dementia.
3. Have previously or are currently receiving other disease-modifying treatments, or participating in clinical studies of other new drugs or therapies.
4. Subjects who have used drugs that may affect Parkinson's symptoms, potentially impact autonomic nervous function, or influence safety evaluation within the past 3 months.
5. Subjects with clinically significant or unstable medical or surgical conditions that may prevent safe completion of treatment or affect treatment outcomes.
6. Recurrent stroke that has been previously suffered from or is currently under treatment
7. Brain magnetic resonance imaging at the time of screening showed other significant pathological findings, including but not limited to: cerebral hemorrhage, acute phase cerebral infarction, aneurysm, vascular malformation, infectious lesions, brain tumors, or other space-occupying lesions (meningiomas or arachnoid cysts with a maximum diameter of less than 1 cm do not need to be excluded).
8. Subjects meeting any of the following criteria indicating a more severe condition: Speech impairment determined by a score of ≥3 on Question 1 of the UMSARS questionnaire; Swallowing impairment determined by a score of ≥3 on Question 2 of the UMSARS questionnaire; Gait impairment determined by a score of ≥3 on Question 7 of the UMSARS questionnaire; Falling more than once per week determined by a score of ≥3 on Question 8 of the UMSARS questionnaire.
9. The subject has a history of current drug and/or alcohol abuse (within 12 months prior to trial enrollment).
10. The subject is known to be allergic to the investigational drug; or has a history of allergies to drugs such as antibiotics.
11. Screening results show active viral infections, including positivity for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), Hepatitis B Core Antibody, and Hepatitis C Virus (HCV).
12. Accompanied by severe hepatic insufficiency, renal insufficiency, or severe cardiac insufficiency (Severe hepatic insufficiency refers to alanine aminotransferase (ALT) values ≥ 2.0 times the upper limit of normal or aspartate aminotransferase (AST) values ≥ 2.0 times the upper limit of normal; Severe renal insufficiency refers to serum creatinine ≥ 1.5 times the upper limit of normal or estimated glomerular filtration rate (eGFR) < 40 ml/min/1.73 m²; Severe cardiac insufficiency refers to New York Heart Association (NYHA) functional classification grade 3-4).
13. Subjects with thrombocytopenia within three months, subjects with other bleeding disorders or receiving anticoagulation therapy (excluding aspirin not exceeding 100 mg per day)
14. Subjects who are pregnant, lactating, or possibly pregnant and planning to become pregnant
15. History of bipolar disorder, major depressive disorder, schizophrenia, or other psychotic disorders
16. Subjects who are clinically judged to have suicidal ideation at the time of screening, or who have attempted suicide within 6 months prior to screening.
17. Those with surgical contraindications (such as having previously received a cochlear implant, pacemaker, defibrillator, stereotactic neuroablation, or having previously been implanted with similar products unilaterally or bilaterally, etc.), or those who have undergone other surgeries within the past six months that the investigator believes may impact this trial, or those with other neurosurgical contraindications.
18. Clinically significant heart disease-related indicators are defined as: myocardial infarction, heart failure with NYHA class III or IV, uncontrolled coronary artery spasm, severe and uncontrolled ventricular arrhythmia, or evidence of acute ischemia or abnormal conduction system on electrocardiogram within 6 months prior to enrollment.
19. Subjects with malignant tumors
20. Family history of congenital or hereditary immunodeficiency diseases
21. Participants assessed by the investigator as having poor compliance
22. Suffering from a serious illness, or having any other condition that endangers the safety of the subject or affects the investigator's assessment.
Click below“Read the Original Text”，View More Clinical Trial Recruitment Information！